Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses

BACKGROUND: The phase II TALAPRO-1 study (NCT03148795) demonstrated durable antitumor activity in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). Here, we detail the safety profile of talazoparib. PATIENTS AND METHODS: Men received talazoparib 1 mg/day (moderate...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehra, Niven, Fizazi, Karim, de Bono, Johann S, Barthélémy, Philippe, Dorff, Tanya, Stirling, Adam, Machiels, Jean-Pascal, Bimbatti, Davide, Kilari, Deepak, Dumez, Herlinde, Buttigliero, Consuelo, van Oort, Inge M, Castro, Elena, Chen, Hsiang-Chun, Di Santo, Nicola, DeAnnuntis, Liza, Healy, Cynthia G, Scagliotti, Giorgio V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526483/
https://www.ncbi.nlm.nih.gov/pubmed/36124924
http://dx.doi.org/10.1093/oncolo/oyac172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526483/
https://www.ncbi.nlm.nih.gov/pubmed/36124924
http://dx.doi.org/10.1093/oncolo/oyac172

Ejemplares similares